Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.

IN RE LORAZEPAM & CLORAZEPATE ANTITRUST LITIGATION

United States District Court, District of Columbia


May 15, 2003

IN RE: LORAZEPAM & CLORAZEPATE ANTITRUST LITIGATION, THIS ORDER APPLIES TO: HEALTH CARE SERVICE CORPORATION, ET AL., PLAINTIFFS,
v.
MYLAN LABORATORIES, INC., ET AL., DEFENDANTS. BLUE CROSS BLUE SHIELD OF MINNESOTA, BLUE CROSS BLUE SHIELD OF MASSACHUSETTS, AND FEDERATED MUTUAL INSURANCE COMPANY, PLAINTIFFS, V. MYLAN LABORATORIES, INC. ET AT., DEFENDANTS.

The opinion of the court was delivered by: Thomas F. Hogan, Chief United States District Judge

ORDER

The Court issued an Order on May 12, 2003 [Civ. No. 99ms0276 docket # 400] regarding the presentation of oral arguments on the Defendants' Motion to Dismiss Plaintiffs' Second Amended Complaint Pursuant to Federal Rule of Civil Procedure 12(b)(6) [Civ. No. 01-2646 docket # 26]. It is hereby

ORDERED that the Court's Order of May 12, 2003 is modified as follows: Defendants shall proceed first and shall limit their argument to thirty (30) minutes. Plaintiff Health Care Service Corporation shall then have fifteen (15) minutes to respond. Plaintiffs Blue Cross Blue Shield of Minnesota, Blue Cross Blue Shield of Massachusetts, and Federated Mutual Insurance Company shall proceed next and shall also have a total of fifteen (15) minutes to respond. Any reply time for Defendants shall be reserved from their original argument allocation of thirty (30) minutes.

SO ORDERED.

20030515

© 1992-2003 VersusLaw Inc.



Buy This Entire Record For $7.95

Official citation and/or docket number and footnotes (if any) for this case available with purchase.

Learn more about what you receive with purchase of this case.